This study is the first to report that cariprazine, a D3/D2 receptor partial agonist, increases the efficacy of MX (an ABCG2 substrate) in the ABCG2 overexpressing cancer cell lines H460-MX20 and S1M1-80. Here, MX1 is linked to cancer.